Pipeline

Promethera® Biosciences’ pipeline of treatments for liver diseases

The product portfolio includes potential treatments for liver diseases such as ACLF, NASH and fibrosis.

Technologies
Indications
R&D
Preclinical
Phase 1
Phase 2
Phase 3
MA/NDS
Cell therapies
Technologies
Indications
R&D
Preclinical
Phase 1
Phase 2
Phase 3
MA/NDS
ACLF
Acute-on-chronic liver failure
Technologies
Indications
R&D
Preclinical
Phase 1
Phase 2
Phase 3
MA/NDS
NASH/Fibrosis
Non-alcoholic steatohepatitis
Technologies
Indications
R&D
Preclinical
Phase 1
Phase 2
Phase 3
MA/NDS
Tissue Repair
Biologicals
Technologies
Indications
R&D
Preclinical
Phase 1
Phase 2
Phase 3
MA/NDS
NASH/Fibrosis
Non-alcoholic steatohepatitis

Discover more about each technology and their respective therapeutic potential

HepaStem

Cell therapy as an alternative to liver transplantation

H2Stem®

Cell therapy for tissue repair

Atrosimab

Antibody therapy for multiple indications